National Blood Clot Alliance Medical and Scientific Advisory Board
Gary E. Raskob, Ph. D., M.Sc. Dean, College of Public Health Professor, Epidemiology and Medicine University of Oklahoma Health Sciences Center
Dr. Gary Raskob is Dean of the College of Public Health, and a Professor of Epidemiology and Medicine, at the University of Oklahoma Health Science Center in Oklahoma City, OK. He specializes in research and treatment of blood clotting disorders and the development of antithrombotic drugs. He also serves as a consultant in clinical research and drug development for the pharmaceutical and biotechnology industry and has played a critical role in developing clinical practice guidelines for numerous specialty organizations.
In addition, he has authored or coauthored over 200 publications on the prevention, diagnosis and treatment of thromboembolic disease, including 14 articles in the New England Journal of Medicine. His expertise in the field of thrombotic disorders and diagnosis, his educational background, and his experience in dealing with government and pharmaceutical institutions make him a valuable asset to every facet of our organization. Gary has a Ph.D. in pharmaceutical sciences from the University of Oklahoma and a M.Sc. in clinical from epidemiology from McMaster University in Hamilton, Canada, and currently resides in Oklahoma City, OK.
Jack Ansell, MD. New York, NY.
Dr. Ansell is the Chairman of the Department of Medicine at Lenox Hill Hospital in New York City. Before joining Lenox Hill Hospital, Dr. Ansell was Professor of Medicine at Boston University School of Medicine and Vice Chairman for Clinical Affairs of the Department of Medicine. See related news story.
After receiving his medical degree from the University of Virginia School of Medicine in Charlottesville, Virginia, Dr. Ansell completed an internship and residency at Tufts New England Medical Center in Boston, Massachusetts. Dr. Ansell then completed a fellowship in hematology at Boston University and in hematology/hemostasis at Boston’s Veterans Administration Hospital.
Dr. Ansell’s main areas of interest and research include hemostasis and thrombosis, with a special emphasis on thrombotic disorders and antithrombotic therapy. He has had a continued interest and involvement in the application of new modes of delivering and monitoring anticoagulants, particularly in the management of oral anticoagulant therapy.
Dr. Ansell has approximately 170 publications in notable journals such as Annals of Internal Medicine, The New England Journal of Medicine, and The Journal of the American Medical Association. His publishing activity includes reviews, editorials, textbooks, videos, abstracts and letters. He serves as an associate editor for the Journal of Thrombosis and Thrombolysis and as an editorial consultant for such journals as The New England Journal of Medicine, Blood, Thrombosis and Haemostasis, and Circulation.
Dr. Ansell is the founder and Chair of the Anticoagulation Forum, a network of anticoagulation clinics throughout North America, and is a member of a number of professional organizations including the American College of Physicians (Fellow); the American Society of Hematology; the International Society of Thrombosis and Hemostasis and its Scientific Subcommittee on Haemostasis Testing; the American Heart Association (Fellow), and the American Medical Association. Dr. Ansell also serves as Chair of the Committee on Managing Oral Anticoagulation for the American College of Chest Physicians Consensus Conference on Antithrombotic Therapy.
Dr Bauer is Professor of Medicine, Harvard Medical School. His hospital positions include Chief, Hematology Section, VA Boston Healthcare System, and Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center in Boston. Dr Bauer received his medical degree from Stanford University School of Medicine in Stanford, California. He completed his residency in medicine at the University of Chicago Hospitals and Clinics in Illinois. He was a Fellow in Medical Oncology and a Clinical/Research Fellow in the Division of Thrombosis and Hemostasis at Dana Farber Cancer Institute and was also a Clinical/Research Fellow in the Hematology-Oncology Division at Beth Israel Deaconess Medical Center. Dr Bauer’s research interests include elucidation of the mechanisms leading to the development of a prethrombotic state and clinical evaluation of new antithrombotic drugs. Dr Bauer previously served as Chairman of Council of the International Society on Thrombosis and Haemostasis (ISTH) and Vice-President and Scientific Program Chair (Clinical) for the XXIInd ISTH Congress in Boston in July 2009. Dr Bauer has published over 200 original reports, reviews, and book chapters.
David Garcia, MD , Director of the Adult Hemophilia Treatment Program, Director of the Anticoagulation Management Service
Dr. David Garcia is a Fellow in the Division of Hematology at the University of Washington. Dr. Garcia is the President of the Anticoagulation Forum, a national interest group focused on the prevention and treatment of thromboembolic disease. His primary research interests include the relationship of cancer and thrombosis, the treatment of warfarin-associated coagulopathy, and the risks and benefits of peri-procedural anticoagulation. Dr. Garcia has been an invited speaker at several international meetings and has authored or co-authored more than 30 peer-reviewed publications in high-impact journals such as Blood, Annals of Internal Medicine, Archives of Internal Medicine, Chest, Thrombosis and Thrombolysis, the British Journal of Hematology and the Journal of the American College of Cardiology.
Neil A. Goldenberg, MD, PhD All Children’s Hospital Johns Hopkins Medicine (ACH JHM) and All Children’s Research Institute
Dr. Goldenberg is Director of Research at All Children’s Hospital Johns Hopkins Medicine (St. Petersburg, FL) as well as Chief Research Officer of the All Children’s Research Institute. He is an Associate Professor of Pediatrics at the Johns Hopkins University School of Medicine, and directs the Pediatric Thrombosis Program at ACH JHM.
Dr. Goldenberg holds a Ph.D. in Clinical Investigation from the University of Colorado, and is a former American Society of Hematology (ASH) Scholar and faculty member of the ASH Clinical Research Training Institute. He is the Principal Investigator or oversight committee chair for several NIH- and industry-sponsored multicenter clinical trials. He has co-authorednumerous international clinical and clinical research guidelines and scientific statements, including the 2012 “Chest” guidelines. Dr. Goldenberg is also a current co-chair of the Pediatric and Neonatal subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee.
Dr. Heit is Professor of Medicine at the Mayo Clinic College of Medicine, where he serves in multiple capacities. He is the Director of the Mayo Clinic General, Special and DNA-diagnostic Coagulation Laboratories and Coagulation Clinic; Chair of the Division of Hematology Coagulation Disease Oriented Group and Program Director for the NIH K12 Vascular Medicine Clinical Research Training Program. Dr. Heit is a staff consultant within the Divisions of Cardiovascular Diseases (Section of Vascular Disease) and Hematology (Section of Hematology Research), Department of Internal Medicine and the Divisions of Hematopathology and Laboratory Genetics, Department of Laboratory Medicine and Pathology. Dr. Heit is the Founder and former Director of both the Mayo Clinic Thrombophilia Center and the Mayo Clinic Chronic Anticoagulation Management Clinic. He is also Co-Founder and Co-Director of the Mayo Clinic Special Coagulation DNA-diagnostic Laboratory.
He is the Principal Investigator on 5 NIH grants and Co-Investigator on 2 NIH grants, addressing the epidemiology (including the genetic epidemiology) and mechanisms of venous thromboembolism and thrombophilia in white and African-American populations, the role of estrogens and platelets in atherosclerosis and bleeding disorders in women.
Dr. Heit has written over 160 peer-reviewed articles, invited papers or book chapters. He has delivered presentations at various medical conferences in the US and abroad, and has served as a member of NIH study sections, as a member of the American College of Chest Physicians Consensus Conference on Antithrombotic and Thrombolytic Therapy since 1995, as a reviewer for 28 medical journals, as Associate Editor for the journal Thrombosis Research, and as Co-Chair of the National Quality Forum/Joint Commission Steering Committee on Venous Thromboembolism Prevention and Management. Dr. Heit is married, and has two children and six grandchildren.
Dr. Andra H. James is a maternal-fetal medicine specialist, Professor and Vice Chair of Research in the Department of Obstetrics and Gynecology at the University of Virginia. Her practice, research and publications focus on reproductive issues among women with bleeding and clotting disorders.
Dr. James is involved both nationally and internationally in activities to improve healthcare for women with bleeding and clotting disorders. Besides serving on the Medical and Scientific Advisory Board (MASAB) of NBCA, she currently serves on the Medical and Scientific Advisory Committee (MASAC) of the National Hemophilia Foundation (NHF). She is also Co-Chair of the Women’s Issues Scientific Subcommittee of the International Society on Haemostasis and Thrombosis, President of the Foundation for Women and Girls with Blood Disorders (FWGBD), and on the VWD & Rare Bleeding Disorders Committee of the World Federation of Hemophilia. She has served on the National Institutes of Health (NIH) National Heart Lung and Blood Institute’s Women with Bleeding Disorders Working Group and their Von Willebrand Disease Expert Panel.
Dr. James has published over 100 articles in various well known journals, as well as co-authored a book with Dr. Thomas L. Ortel and Dr. Victor F. Tapson, entitled 100 Questions and Answers About Deep Vein Thrombosis and Pulmonary Embolism, published in 2008.
Scott Kaatz is the Chief Quality Officer and head of the Academic Hospital Medicine program at Hurley Medical Center in Flint Michigan. He attended medical school at Michigan State University and completed his residency in internal medicine at Henry Ford Hospital. Later in his career, he earned his Master’s degree in Evidence-Based Health Care from Oxford University.
He has a long standing research interest in anticoagulation and thromboembolic disease and was the Medical Director of the Anticoagulation Clinics for the Henry Ford Health System in Detroit, MI for15 years.
Dr. Kaatz is a fellow of American College of Physicians, as well as a member of the Society for General Internal Medicine, the Society of Hospital Medicine, the International Society of Thrombosis and Heamostasis and the American Medical Association. He serves on the boards of the National Certification Board of Anticoagulation Providers, AC Forum and the Medical Scientific Advisory Board of the National Blood Clot Alliance.
He has participated in many research studies with an emphasis on anticoagulation and venous thromboembolism prevention, diagnosis and treatment; and has published numerous abstracts, articles and book chapter in this field.
Jeffrey A. Kline, MD, Vice Chair of Research, Dept. of Emergency Medicine and Professor, Dept. of Cellular and Integrative Physiology at Indiana University School of Medicine
Dr. Kline is the Vice Chair of Research at the Department of Emergency Medicine an emergency physician at the Indiana University School of Medicine who conducts clinical and translational research to improve the therapeutic index of the diagnostic evaluation of patients with possible venous thromboembolism and treatment of patients with proven venous thromboembolism.
Dr. Kline’s research focuses on screening, risk stratifying and treating pulmonary embolism (PE). He has built and patented a device to help diagnose or exclude PE based upon instant analysis of exhaled partial pressures of CO2 and O2. Dr. Kline received his medical doctorate from the Medical College of Virginia in 1990. He completed residency training in emergency medicine at the Carolinas Medical Center in 1993 and then a research fellowship in 1994.
Peter Kouides MD, Medical and Research Director, Mary M. Gooley Hemophilia Center Inc., Rochester, NY; Attending hematologist, Rochester General Hospital; Clinical Professor of Medicine, University of Rochester School of Medicine Clinical Associate Professor of Medicine, Roswell Park Memorial Cancer Institute
Over the years, Peter Kouides, MD, has served as principal investigator on a number of studies primarily dealing with the gynecological and obstetrical complications of von Willebrand Disease (VWD) as well as thrombotic disorders of pregnancy. Dr. Kouides is also co-chair of the Centers for Disease (CDC) Universal Data Collection (UDC) study of women with bleeding disorders. He serves on the CDC UDC working group and is past co-chair of the International Society of Thrombosis and Hemostasis Women’s Hemostasis and Thrombosis Issues committee. He recently completed a textbook of bleeding disorders in women co-edited with Professors Christine Lee and Rezan Kadir. In 2005, Dr. Kouides received a National Hemophilia Foundation (NHF) Award of excellence for work in Women with bleeding disorders and then in 2009 the NHF Physician of the Year award. He was the 2010 recipient of the Rochester General Hospital Father Norton Physician of the Year award.
Dr. Kouides is also an appointed recent past member of the NHF Medical and Scientific Advisory Committee and recent past member of the U.S. Health and Human Services Advisory Committee on Blood Safety and Availability. He is a member of the Medical Advisory Committee for the Foundation for Women and Girls with Blood Disorders. He is immediate past-president of the Hemophilia and Thrombosis Research Society (HTRS) of North America. He is chair of the New England Hemophilia Treatment Centers Executive committee. He was co-chair of the first biennial Thrombosis and Hemostasis Summit of North America (THSNA) in 2012 and is co-chair for the 2014 meeting. Dr. Kouides is co-editor of NHF’s HemeAware magazine and the journal Seminars in Hemostasis and Thrombosis. He serves on the editorial board of Haemophilia. Dr. Kouides is the medical director of the Mary M. Gooley Hemophilia Treatment Center since 1998 and is also the team leader for the Mary M. Gooley Hemophilia Treatment Center World Federation of Haemophilia Twinning Program with Bishkek, Kyrgyzstan in setting up a National Haemophilia program and Treatment Center with visits in 2009, 2011, and 2013.
Gregory Maynard, Clinical Professor and Chief, Division of Hospital Medicine, UC San Diego Director, UCSD Center for Innovation and Improvement Science
Greg Maynard is a Clinical Professor of Medicine and Chief of the division of Hospital Medicine at the University of California, San Diego. He is active on both a local and national level in many efforts to improve the quality and safety of the care delivered to inpatients. Dr. Maynard’s special interests include optimizing prevention and management of venous thromboembolism (VTE), improving glycemic control and reducing hypoglycemia in the hospital, and transitions of care. Dr. Maynard’s research interests parallel his QI efforts, and he is principal investigator or otherwise involved in several funded research efforts.
He acts as a leader and mentor in the Society of Hospital Medicine (SHM), AHRQ, ASHP, and IHI national collaboratives to improve VTE prevention He is a mentor / investigator for Project BOOST, an SHM initiative to improve transitions in care, and is also a mentor / investigator for the SHM Glycemic Control collaborative. He acted as the lead of the SHM Glycemic Control Task Force, generating the SHM Glycemic Control Resource Room and the supplement in Journal of Hospital Medicine reflecting the Task Force work, and has published numerous peer reviewed papers on the subject.
Dr. Maynard was recently recognized as one of ACP Hospitalist’s top hospitalists, and San Diego county “Top Doc”, and has been recognized nationally for his work in Quality Improvement / Research by the Society of Hospital Medicine, the National Association of Public Hospitals, the Venous Disease Coalition, and the North American Thrombosis Forum. He was recently named as the Director of the UCSD Center for Innovation and Improvement Science.
Gerald V. Naccarelli, Pennsylvania State University College of Medicine/Milton S. Hershey Medical Center
Gerald V. Naccarelli M.D. was born in Philadelphia, Pa, received his B.S. in Biology from St. Joseph’s University and his M.D. degree from the Pennsylvania State University College of Medicine in Hershey. He was an Internal Medicine Resident at the North Carolina Baptist Hospital/Bowman Gray School of Medicine (Wake Forest University). He was a Fellow in Cardiology and Chief Resident in Medicine at the Penn State University College of Medicine followed by a UPSHS postdoctoral Fellow in Cardiac Electrophysiology at the Indiana University School of Medicine. Prior to his current position at Hershey, he was Director of Clinical Electrophysiology and Vice-Chairman of Cardiology at the University of Texas Medical School at Houston. In 1995 he moved to Hershey and currently is the Bernard Trabin Chair in Cardiology, Professor of Medicine, Chief of the Division of Cardiology, and Associate Clinical Director of the Heart and Vascular Institute at the Pennsylvania State University College of Medicine/Milton S. Hershey Medical Center.
Dr. Naccarelli had been a member of multiple national committees of the American Heart Association (AHA), American College of Cardiology (ACC) and the Heart Rhythm Society (HRS). He is past-president of NASPE (HRS) and a past-member of the Board of Trustees of the American College of Cardiology and HRS. He served on the ABIM Subspecialty Board on Cardiovascular Diseases from 1999-2005 and currently is the Chair of the ABIM Cardiovascular Diseases SEP Committee. He was a charter member of CMS’ Ambulatory Payment Classification (APC) advisory panel. He is an elected member of the Association of University Cardiologists (AUC) and member and Past-President of the Association of the Professors of Cardiology (APC).
Dr. Naccarelli is internationally recognized for his clinical, teaching and research contributions. He has been listed in the best Doctors of America (Cardiovascular Diseases – Electrophysiology) since 1992 and America’s Top Doctors (Castle Connolly) since 2001. Dr. Naccarelli has trained 27 fellows in cardiac electrophysiology and over 125 fellows in Cardiology over his 31 years of clinical practice.
Dr. Naccarelli’s research interests are in atrial fibrillation, clinical arrhythmia trials, implantable devices for treating arrhythmias and congestive heart failure, antiarrhythmic drug development and autonomic aspects of arrhythmogenesis. He has published over 550 peer review papers, book chapters, reviews and abstracts and is the author of 3 books. Dr Naccarelli has been involved in the clinical development and approval of all the antiarrhythmic agents released in the USA over the last 30 years. He has been an active consultant to over 25 companies in medical industry and is currently on the steering committee of 6 major clinical trials.
He is a recipient of the Paul Dudley White Award from the American Heart Association and the Nycomed Amersham Award for Excellence Honoring Leadership, Achievement and Commitment to the Profession from the American College of Cardiovascular Administrators and the 2012 Clarence E. Shaffrey, S.J. Award, from St. Joseph’s University, in recognition of his service and outstanding achievement in the medical profession. He is currently on the editorial board of 8 scientific journals in addition to being Associate Editor of the Journal of Interventional Cardiac Electrophysiology and a past Associate editor of Circulation.
Dr. Naccarelli and his wife, Terry, have a daughter, Michele, and a son, Matthew both of whom work in Philadelphia. Outside of medicine, Dr. Naccarelli’s hobbies include golf, hockey card collecting, enology and playing the guitar.
Edith A. Nutescu, Pharm.D., FCCP, is Clinical Professor in the Department of Pharmacy Practice and Center for Pharmacoeconomic Research at the University of Illinois at Chicago College of Pharmacy. She also serves as the Clinical Manager of the Antithrombosis Center at the University of Illinois at Chicago Medical Center. Dr. Nutescu earned her Pharm.D. degree with high honors at the University of Illinois at Chicago College of Pharmacy. After graduation, Dr Nutescu went on to complete an American Society of Health-System Pharmacists (ASHP)–accredited Pharmacy Practice Residency at Lutheran General Hospital–Advocate Health Care and a Primary Care Specialty Residency at the University of Illinois at Chicago Medical Center.
As a clinician and educator, Dr. Nutescu has contributed extensively to the care of patients and the education of students and health care providers on topics related to cardiovascular therapeutics. Dr. Nutescu maintains an active clinical practice and research program. Her research and practice interests are in the areas of comparative effectiveness, health services and outcomes, with emphasis in cardiovascular diseases, stroke, thrombosis, and antithrombotic therapies. Dr Nutescu has authored or co-authored over 100 scientific articles, book chapters, and abstracts published in the science and medical literature and has served as a reviewer for the literature in her field.
Dr. Nutescu’s research has been funded by the Department of Health and Human Services and the National Center for Research Resources and is a recipient of the Ruth L. Kirchstein National Research Service Award for 2009-2011. Dr. Nutescu is the recipient of the American College of Clinical Pharmacy’s 2009 Clinical Practice Award and the American Society of Health System Pharmacists, Section of Home and Ambulatory Care Practitioners 2010 Distinguished Service Award.
Lynn B. Oertel, M.S. ANP-C, CACP, is a clinical nurse specialist with The Anticoagulation Management Service at Massachusetts General Hospital in Boston, Massachusetts. Massachusetts General Hospital has one of the largest and most experienced warfarin management clinics in the United States.
Ms. Oertel received her Master of Science in Nursing degree from Boston University. She has additional certification from the American Nurse’s Credentialing Center as an adult nurse practitioner. Ms. Oertel is a certified anticoagulation care provider (CACP) and is nationally recognized as an expert nurse clinician in anticoagulation therapy management. She has nearly 25 years of clinical and research experience related to anticoagulant therapy management.
Ms. Oertel is a founding member of the Board of Directors of the National Certification Board for Anticoagulation Providers, the only multidisciplinary national certification for anticoagulation care providers. She is currently a member of the Board of Directors of the Anticoagulation Forum and co-editor and chapter author of the third edition textbook Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines.
Frederick R. Rickles, MD, FACP, Professor of Medicine, Pediatrics and Pharmacology and Physiology, The George Washington University, Washington, DC
Dr. Rickles received his MD degree from the University of Illinois and trained in internal medicine and hematology at the University of Rochester School of Medicine, Rochester, NY. He was Director of the Hemostasis and Thrombosis Research Laboratory at Walter Reed Army Institute of Research from 1971-1974, and was on the faculty of the University of Connecticut School of Medicine from 1974-93, where he was the American Red Cross Professor of Medicine and Laboratory Medicine and Chief, Hematology-Oncology.
From 1993-1998, he was Deputy Chief, Hematologic Diseases at the Centers for Disease Control and Prevention, Professor of Medicine and Pediatrics at Emory University and Director of the Emory Hemophilia and Thrombosis Center, in Atlanta, GA. From 1998-2003, Dr. Rickles was Associate VP for Health Research at The George Washington University and from 2003-2006, he was the CEO of FASEB. Since 2006, Dr. Rickles is a consultant to the Healthcare group of Noblis, a non-profit technology and science company working in the public interest, and to Eisai, Johnson & Johnson, Genmab, ISIS and Pharmacyclics on the development of new drugs for the prevention and treatment of thrombosis and bleeding disorders.
He is an Editor of the book Cancer and Thrombosis and the author of over 120 papers in refereed journals, 10 book chapters and 20 reviews in his areas of interest, including hemophilia, von Willebrand Disease, rare coagulation disorders and thrombosis in cancer. He continues to investigate the regulation of TF and Vascular Endothelial Growth Factor gene expression in cancer and has collaborated on the design of novel therapeutic agents that inhibit these pathways. He has been on the editorial board of Thrombosis and Haemostasis, Blood Coagulation and Fibrinolysis, Journal of Thrombosis and Hemostasis and Supportive Cancer Therapy. Dr. Rickles has served on study sections for the NIH, DoD, ACS and the AHA and was a founding Chairman of the Subcommittee on Coagulation and Malignancy for the ISTH and served on the Subcommittee of Vascular Biology and Thrombosis for the ASH. He is a member of AACR and was VP for Medical and Scientific Affairs for the NHF and a founding member of the Hemophilia and Thrombophilia Research Society.
Associate Professor of Medicine and Pathology Associate Faculty, Armstrong Institute for Patient Safety and Quality Care Medical Director, Johns Hopkins Anticoagulation Management Service and Outpatient Clinics Medical Director, Special Coagulation Laboratory Chairman, Venous Thromboembolism Guideline Committee, National Comprehensive Cancer Network Johns Hopkins Medical Institutions Baltimore, Maryland
Dr Streiff’s research focuses on the prevention and treatment of venous thromboembolism (VTE) and evidence-based management of anticoagulation. He chairs the Venous Thromboembolism Guideline Committee for the National Comprehensive Cancer Center Network and has served on several international consensus panels to develop evidence-based guidelines for the management of VTE. As a member of the Johns Hopkins VTE Collaborative he spearheaded efforts to develop evidence-based specialty-specific VTE Prophylaxis computer decision support “smart order sets” that have led to dramatic improvements in VTE prophylaxis across Johns Hopkins Medicine.
Dr. Streiff and the Anticoagulation Management Service team have played a key role in developing evidence-based guidelines and electronic order sets for anticoagulation therapy at Johns Hopkins Medical Institutions. He has published over 100 articles and book chapters focusing on topics in VTE management and thrombosis and hemostasis and delivered over 250 lectures at local, national and international meetings.
Darren M. Triller Pharm.D., Sr. Project Director, IPRO, CMS designated QIO for New York State
Dr. Triller is Senior Project Director for IPRO, the Centers for Medicare and Medicaid Services (CMS)-designated Quality Improvement Organization (QIO) for NYS. In that capacity, Dr. Triller leads/contributes to multiple drug safety/quality improvement initiatives at local/state/national levels. He assembled and currently directs the NYS Anticoagulation Coalition, a multidisciplinary group of over 100 clinicians and healthcare professionals collaborating to enhance the quality and safety of anticoagulant (AC) therapy.
This effort aligns with the mission of the National Blood Clot Alliance (NBCA) and, in addition to promoting improved patient care, affords exposure for the NBCA across the QIO network of 53 states and US territories. In addition, the CMS-funded effort in NY provides direct technical assistance to AC providers across the state, including data analytic services and the provision of detailed provider performance reports characterizing warfarin time in therapeutic range (TTR) and clinical outcomes (e.g. hospitalization for thrombosis or bleeding events). This technical knowledge is also disseminated across other QIOs, providing a model for improvement in warfarin management at the national level.
In addition to serving on the NBCA MASAB, Dr. Triller contributes to several national efforts to develop, test, and implement drug-related quality measures and to promote quality improvement across the pharmacy community. He presently serves as a member of the Technical Expert Panel (TEP) for the CMS medication quality measures development and management program led by Florida Medical Quality Assurance, Inc. (FMQAI). He also contributes to medication quality measure TEPs for the Pharmacy Quality Alliance (PQA) and the American Society of Health-System Pharmacists (ASHP). He has served as president of the NYS Chapter of the American College of Clinical Pharmacy (ACCP) and is past chair of the NY Pharmacy Conference.
Dr. Triller received both his B.S. and Pharm.D. degrees from Albany College of Pharmacy and Health Sciences (ACPHS) in Albany, NY. He completed a post-doctoral fellowship in drug safety at ACPHS, and has led numerous funded studies and peer-reviewed publications on the topics of drug safety and quality improvement throughout his 20+ year career in pharmacy. He holds an adjunct clinical faculty appointment at the college, and is an active author, speaker, and advocate for drug safety topics.
Dr. Weitz is a Professor of Medicine and Biochemistry at McMaster University and Director of the Henderson Research Centre. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz now focuses his clinical work in the area of thrombosis. He holds an Endowed Chair in Cardiovascular Research at McMaster University, which is funded by the Heart and Stroke Foundation of Ontario. He also holds the Canada Research Chair (Tier 1) in Thrombosis.
Dr. Weitz received the Medal in Medicine from the Royal College of Physicians and Surgeons of Canada in 1991, the Distinguished Scientist Award from the Heart and Stroke Foundation of Ontario in 1999, the Research Achievement Award from the Canadian Cardiovascular Society in 2006, and the Jack Hirsh Award for Outstanding Academic Achievement from McMaster University in 2008. He is a member of the American Federation of Medical Research, the American Society for Clinical Investigation, and the Association of American Physicians and gave the Davidson Lecture at the University of Edinburgh in 2000, the Nossel Memorial Lecture at Columbia University in New York in 2003, and the Mosesson Lecture at the Blood Research Institute in Milwaukee in 2008.
Dr. Weitz directs a well-funded research laboratory that focuses on the biochemistry of blood coagulation and fibrinolysis as it applies to venous and arterial thrombosis. A former Vice-President of Research for the Heart and Stroke Foundation, member of the Board of Directors of the Heart and Stroke Foundation of Ontario, Chair of the Scientific Review Committee for the Heart and Stroke Foundation of Canada, member of the Executive Council on Thrombosis of the American Heart Foundation, and Chair of the Council on Vascular Biology for the American Society of Hematology, Dr. Weitz has published over 265 peer-reviewed papers and 35 textbook chapters.
Diane L. Wirth MS ANP-BC CACP, Provider Health Services
Diane L. Wirth MS ANP-BC CACP is a nurse practitioner with Provider Health Services which provides primary care to long term care and rehabilitation facilities. Ms. Wirth is recognized by her peers as an expert in anticoagulation management of patients. Previously Ms. Wirth was employed at Grady Memorial Hospital (2010-2013) where she managed the department of cardiology and anticoagulation clinic as well as provided clinical support to the department.
Ms. Wirth was the managing NP in establishing the heart failure program which was awarded the GAGE award in May of 2013. Ms. Wirth spent the first 17 years of her career at Emory Healthcare, the last 8 years in which she managed the 8 anticoagulation clinics with 3000+patients and established a large virtual clinic with over 300 patients trained to self test their INR’s at home.
Ms. Wirth received her Master’s in Science/NP degree from Emory University and is credentialed as an adult nurse practitioner through American Nurse Credentialing Center. Ms. Wirth was appointed to the Anticoagulation Board of Directors in 2013 and is a certified anticoagulation provider (CACP). She serves as the treasurer on the Board of Directors of the National Certification Board for Anticoagulation Providers. Ms. Wirth has worked as a team member in a joint venture between CDC and the National Blood Clot Alliance to develop educational curriculum for thrombosis and atrial fibrillation. Ms. Wirth is a patient education provider/trainer for Alere Home Monitoring and has trained hundreds of patients to self test INR’s in their home.
Ms. Wirth has published articles on genetic mutations while at Emory Healthcare and reductions of CHF readmissions. Research interests include anticoagulation, patient education and reduction of hospital admissions. She worked with a team of experts to develop on line curriculum, Stop the Clot: What Every Health Care Provider Should Know. Ms. Wirth co-authored a chapter in the third edition text book Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines.